HOW TO MANAGE TOXICITY AND ASSESS THE ANSWER TO IMMUNOTHERAPY IN MELANOMA PATIENTS

The immunological therapy of melanoma is going through a phase of great evolution, thanks to the important results obtained in many clinical studies, starting from 2010, following the introduction of antibodies against immunological checkpoints such as CTLA-4 and, in particular, PD -1. The purpose of this project is to investigate the main scenarios of difficult management of melanoma patients treated with ant-PD-1 antibodies, through examples of interactive clinical situations.